Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 417
- Registration Number
- NCT02332512
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT02329860
- Locations
- 🇨🇳
Jiangsu hengrui medicine CO. LTD, Lianyungang, Jiangsu, China
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
- Conditions
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 336
- Registration Number
- NCT02188082
- Locations
- 🇨🇳
Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China
🇨🇳the Second Hospital of Shandong University, Jinan, Shandong, China
🇨🇳The second affiliated hospital of wenzhou medical university, Wenzhou, Zhejiang, China
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2014-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT02119715
- Locations
- 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 316
- Registration Number
- NCT02012075
- Locations
- 🇨🇳
Gansu Provincial Hospital, Lanzhou, Gansu, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT01994213
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 2400
- Registration Number
- NCT01985165
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳The Second Hospital of Shangdong University, Jinan, Shandong, China
🇨🇳Taizhou Hospital, Taizhou, Zhejiang, China
Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01984489
A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT01976858
- Locations
- 🇨🇳
Beijing tongren hospital, Beijing, Beijing, China
A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT01969357
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China